Help:Needs review/Missing review

From BugSigDB

This is a list of pages that have been marked as Complete but have not yet been reviewed.

16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis
16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis/Experiment 1/Signature 1
16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis/Experiment 1/Signature 2
16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation
16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation/Experiment 1
16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation/Experiment 1/Signature 1
16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation/Experiment 1/Signature 2
16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones
16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 1
16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 1/Signature 1
16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 1/Signature 2
16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 2
16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 2/Signature 1
16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones/Experiment 2/Signature 2
A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer
A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer/Experiment 1
A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer/Experiment 1/Signature 1
A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer/Experiment 1/Signature 2
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 2/Signature 2
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 3
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 3/Signature 1
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 3/Signature 2
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 4
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 4/Signature 1
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 5
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 5/Signature 1
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer/Experiment 5/Signature 2
A prospective microbiome-wide association study of food sensitization and food allergy in early childhood
A prospective microbiome-wide association study of food sensitization and food allergy in early childhood/Experiment 1
A prospective microbiome-wide association study of food sensitization and food allergy in early childhood/Experiment 1/Signature 1
A prospective microbiome-wide association study of food sensitization and food allergy in early childhood/Experiment 2
A prospective microbiome-wide association study of food sensitization and food allergy in early childhood/Experiment 2/Signature 1
A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis
A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 1
A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 1/Signature 1
A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 2
A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis/Experiment 2/Signature 1
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 1
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 1/Signature 1
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 1/Signature 2
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 2
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 2/Signature 1
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 3
A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial/Experiment 3/Signature 1
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 1
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 1/Signature 1
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 2
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 2/Signature 1
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 3
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 3/Signature 1
Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including Pseudomonas Aeruginosa/Experiment 3/Signature 2
Age-specific differential changes on gut microbiota composition in patients with major depressive disorder/Experiment 1
Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen
Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1
Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 1/Signature 1
Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2
Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 1
Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 2/Signature 2
Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3
Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases Bacteroides fragilis Abundance Compared with an Isocaloric Snack in College Freshmen/Experiment 3/Signature 1
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 1
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 1/Signature 1
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 1/Signature 2
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 2
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 2/Signature 1
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 2/Signature 2
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 3
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 3/Signature 1
Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes/Experiment 3/Signature 2
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 2
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome/Experiment 2/Signature 1
Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 1/Signature 2
Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 2/Signature 2
Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 3/Signature 1
Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy/Experiment 4/Signature 1
Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy/Experiment 3/Signature 1
Alterations in the gut microbiotas of children with food sensitization in early life
Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 1
Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 1/Signature 1
Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 1/Signature 2
Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 2
Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 2/Signature 1
Alterations in the gut microbiotas of children with food sensitization in early life/Experiment 2/Signature 2
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19/Experiment 3
Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis
Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1
Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1/Signature 1
Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis/Experiment 1/Signature 2
Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 3/Signature 1
Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 4/Signature 2
Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 5/Signature 1
Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 7/Signature 1
Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 9/Signature 2
Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer/Experiment 10/Signature 1
Alterations of gut microbiome in autoimmune hepatitis
Alterations of gut microbiome in autoimmune hepatitis/Experiment 1
Alterations of gut microbiome in autoimmune hepatitis/Experiment 1/Signature 1
Alterations of gut microbiome in autoimmune hepatitis/Experiment 1/Signature 2
Alterations of gut microbiome in autoimmune hepatitis/Experiment 2
Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients
Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients/Experiment 1
Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients/Experiment 1/Signature 1
Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients/Experiment 1/Signature 2
Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 1
Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 2/Signature 2
Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4
Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza/Experiment 4/Signature 1
Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men/Experiment 5
Altered fecal microbiota composition associated with food allergy in infants
Altered fecal microbiota composition associated with food allergy in infants/Experiment 1
Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 1
Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 2
Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 3
Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 4
Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 5
Altered fecal microbiota composition associated with food allergy in infants/Experiment 1/Signature 6
Altered fecal microbiota composition associated with food allergy in infants/Experiment 2
Altered fecal microbiota composition associated with food allergy in infants/Experiment 2/Signature 1
Altered fecal microbiota composition associated with food allergy in infants/Experiment 2/Signature 2
Altered fecal microbiota composition associated with food allergy in infants/Experiment 3
Altered fecal microbiota composition associated with food allergy in infants/Experiment 3/Signature 1
Altered fecal microbiota composition associated with food allergy in infants/Experiment 3/Signature 2
Altered fecal microbiota composition associated with food allergy in infants/Experiment 4
Altered fecal microbiota composition associated with food allergy in infants/Experiment 4/Signature 1
Altered fecal microbiota composition associated with food allergy in infants/Experiment 4/Signature 2
Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1/Signature 1
Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 1/Signature 2
Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2
Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2/Signature 1
Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 2/Signature 2
Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3
Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3/Signature 1
Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples/Experiment 3/Signature 2
Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components
Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components/Experiment 1/Signature 1
Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components/Experiment 1/Signature 2
Altered intestinal microbiota associated with colorectal cancer
Altered intestinal microbiota associated with colorectal cancer/Experiment 1
Altered intestinal microbiota associated with colorectal cancer/Experiment 1/Signature 1
Altered intestinal microbiota associated with colorectal cancer/Experiment 1/Signature 2
Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome
Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome/Experiment 1
Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome/Experiment 1/Signature 1
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 1
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 1/Signature 1
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 1/Signature 2
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 2
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 2/Signature 1
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 2/Signature 2
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 3
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma/Experiment 3/Signature 1
Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease
Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2
Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 1
Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response/Experiment 2/Signature 2
Analysis of subgingival microbiome of periodontal disease and rheumatoid arthritis in Chinese: A case-control study
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1/Signature 1
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 1/Signature 2
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2/Signature 1
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 2/Signature 2
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 3
Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study/Experiment 3/Signature 1
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 1
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 1/Signature 1
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 1/Signature 2
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 2
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 2/Signature 1
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 2/Signature 2
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 3
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 3/Signature 1
Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study/Experiment 3/Signature 2
Antibiotics at birth and later antibiotic courses: effects on gut microbiota/Experiment 1
Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis
Association of dietary fibre intake and gut microbiota in adults
Association of dietary fibre intake and gut microbiota in adults
Association of dietary fibre intake and gut microbiota in adults/Experiment 1
Association of dietary fibre intake and gut microbiota in adults/Experiment 1
Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 1
Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 1
Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 2
Association of dietary fibre intake and gut microbiota in adults/Experiment 1/Signature 2
Association of dietary fibre intake and gut microbiota in adults/Experiment 2
Association of dietary fibre intake and gut microbiota in adults/Experiment 2/Signature 1
Association of dietary fibre intake and gut microbiota in adults/Experiment 3
Association of dietary fibre intake and gut microbiota in adults/Experiment 3/Signature 1
Association of dietary fibre intake and gut microbiota in adults/Experiment 3/Signature 2
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab/Experiment 1/Signature 1
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab/Experiment 1/Signature 2
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 1
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 1/Signature 1
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 1/Signature 2
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 2
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 2/Signature 1
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 3
Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment/Experiment 3/Signature 1
Body site-typical microbiome signatures/Experiment 1
Body site-typical microbiome signatures/Experiment 2
Body site-typical microbiome signatures/Experiment 2/Signature 1
Body site-typical microbiome signatures/Experiment 2/Signature 2
Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 2/Signature 1
Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 3/Signature 1
Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 4/Signature 1
Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 5/Signature 1
Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study/Experiment 6/Signature 1
Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection
Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1
Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1/Signature 1
Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 1/Signature 2
Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2
Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2/Signature 1
Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection/Experiment 2/Signature 2
Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia
Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia/Experiment 1
Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia/Experiment 1/Signature 1
Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 2/Signature 2
Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 3/Signature 1
Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 3/Signature 2
Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 4/Signature 2
Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 5/Signature 1
Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers/Experiment 5/Signature 2
Characterization and Analysis of the Skin Microbiota in Rosacea: A Case-Control Study/Experiment 1/Signature 2
Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study/Experiment 1/Signature 1
Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients/Experiment 1/Signature 1
Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients/Experiment 1/Signature 2
Chemotherapy-driven dysbiosis in the intestinal microbiome/Experiment 1/Signature 2
Cigarette smoking and the oral microbiome in a large study of American adults/Experiment 1/Signature 2
Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation
Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation/Experiment 1
Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation/Experiment 1/Signature 1
Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation/Experiment 2
Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation/Experiment 2/Signature 1
Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota/Experiment 1/Signature 1
Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers
Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers/Experiment 1
Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing
Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 1
Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 1/Signature 2
Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing/Experiment 2
Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans
Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1
Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1/Signature 1
Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 1/Signature 2
Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 2
Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 2/Signature 1
Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans/Experiment 2/Signature 2
Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing/Experiment 2/Signature 2
Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 2/Signature 1
Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 3/Signature 2
Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 4
Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 4/Signature 1
Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 5
Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli/Experiment 5/Signature 1
Correlation of fecal metabolomics and gut microbiota in mice with endometriosis/Experiment 1/Signature 1
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1/Signature 1
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1/Signature 2
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1/Signature 3
Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation/Experiment 1/Signature 4
Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 1/Signature 1
Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 2/Signature 1
Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis/Experiment 3/Signature 1
Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production
Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production/Experiment 1
Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production/Experiment 1/Signature 1
Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 2/Signature 1
Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease/Experiment 3/Signature 2
Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma/Experiment 1
Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function/Experiment 2
Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns/Experiment 1
Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 1
Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 3/Signature 1
Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4
Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4/Signature 1
Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects/Experiment 4/Signature 2
Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals
Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 1
Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 1/Signature 1
Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 1/Signature 2
Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals/Experiment 2
Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods
Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1
Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1/Signature 1
Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 1/Signature 2
Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 2
Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods/Experiment 2/Signature 1
Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects
Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects/Experiment 1
Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects/Experiment 1/Signature 1
Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects/Experiment 1/Signature 2
Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals/Experiment 1/Signature 1
Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals/Experiment 1/Signature 2
Different functional genes of upper airway microbiome associated with natural course of childhood asthma
Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1
Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1/Signature 1
Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 1/Signature 2
Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 2
Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 2/Signature 1
Different functional genes of upper airway microbiome associated with natural course of childhood asthma/Experiment 2/Signature 2
Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia/Experiment 1/Signature 2
Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women
Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 1
Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 1/Signature 1
Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 2
Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women/Experiment 2/Signature 1
Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 1/Signature 2
Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 2/Signature 1
Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation/Experiment 2/Signature 2
Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure/Experiment 1/Signature 2
Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure/Experiment 2/Signature 1
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 1/Signature 1
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 2/Signature 2
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 3/Signature 1
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 4/Signature 1
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 5/Signature 2
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 7
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 8/Signature 1
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 8/Signature 2
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 9/Signature 1
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 9/Signature 2
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 10/Signature 1
Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma/Experiment 10/Signature 2
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 2
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 3
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 4
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 4/Signature 1
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 5
Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome/Experiment 5/Signature 1
Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment
Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 1
Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 1/Signature 1
Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 1/Signature 2
Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2
Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2/Signature 1
Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment/Experiment 2/Signature 2
Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study
Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study/Experiment 1
Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study/Experiment 1/Signature 1
Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study/Experiment 1/Signature 2
Dysbiosis of human gut microbiome in young-onset colorectal cancer/Experiment 2/Signature 1
Dysbiosis of the Gut Microbiome in Lung Cancer/Experiment 1/Signature 1
Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 2/Signature 1
Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer/Experiment 4/Signature 1
Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients/Experiment 2/Signature 2
Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia
Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia/Experiment 1
Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia/Experiment 1/Signature 1
Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia/Experiment 1/Signature 2
Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis
Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis/Experiment 1
Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis/Experiment 1/Signature 1
Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis/Experiment 1/Signature 2
Early-life gut microbiome and egg allergy
Early-life gut microbiome and egg allergy/Experiment 1
Early-life gut microbiome and egg allergy/Experiment 1/Signature 1
Early-life gut microbiome and egg allergy/Experiment 1/Signature 2
Early-life gut microbiome and egg allergy/Experiment 2
Early-life gut microbiome and egg allergy/Experiment 2/Signature 1
Early-life gut microbiome composition and milk allergy resolution/Experiment 1/Signature 1
Ecological succession in the vaginal microbiota during pregnancy and birth/Experiment 1/Signature 2
Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study/Experiment 1/Signature 2
Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study/Experiment 2/Signature 1
Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 2
Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 2/Signature 2
Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 3
Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 3/Signature 1
Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia/Experiment 3/Signature 2
Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals/Experiment 2/Signature 1
Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals/Experiment 2/Signature 2
Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media/Experiment 1
Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media/Experiment 2/Signature 1
Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model
Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1
Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 1/Signature 1
Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 2
Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 2/Signature 1
Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 3
Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model/Experiment 3/Signature 1
Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice
Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 1
Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 1/Signature 1
Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 1/Signature 2
Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 2
Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 2/Signature 1
Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice/Experiment 2/Signature 2
Effects of PM2.5 exposure during gestation on maternal gut microbiota and pregnancy outcomes
Effects of PM2.5 exposure during gestation on maternal gut microbiota and pregnancy outcomes/Experiment 1
Effects of PM2.5 exposure during gestation on maternal gut microbiota and pregnancy outcomes/Experiment 1/Signature 1
Effects of PM2.5 exposure during gestation on maternal gut microbiota and pregnancy outcomes/Experiment 1/Signature 2
Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 1/Signature 2
Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 3/Signature 1
Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 4/Signature 1
Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients/Experiment 4/Signature 2
Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome/Experiment 4/Signature 1
Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 2/Signature 1
Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection/Experiment 3/Signature 2
Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19/Experiment 4
Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway/Experiment 1/Signature 2
Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study
Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study/Experiment 1
Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study/Experiment 1/Signature 1
Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study/Experiment 1/Signature 2
Environmental exposures and child and maternal gut microbiota in rural Malawi/Experiment 1/Signature 2
Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome
Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 1
Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 1/Signature 1
Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 2
Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 2/Signature 1
Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome/Experiment 2/Signature 2
Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month
Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month/Experiment 1
Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month/Experiment 1/Signature 1
Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month/Experiment 1/Signature 2
Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes
Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes/Experiment 1
Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes/Experiment 1/Signature 1
Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes/Experiment 1/Signature 2
Ethnic variability associating gut and oral microbiome with obesity in children
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1/Signature 1
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 1/Signature 2
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2/Signature 1
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 2/Signature 2
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3/Signature 1
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 3/Signature 2
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 4
Ethnic variability associating gut and oral microbiome with obesity in children/Experiment 4/Signature 1
Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 1/Signature 2
Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 2/Signature 2
Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 3/Signature 2
Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country/Experiment 4/Signature 1
Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions
Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions/Experiment 1
Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions/Experiment 1/Signature 1
Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions/Experiment 2
Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions/Experiment 2/Signature 1
Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers
Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers/Experiment 1
Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers/Experiment 1/Signature 1
Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers/Experiment 1/Signature 2
Evolution of the gut microbiome following acute HIV-1 infection/Experiment 1/Signature 1
Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans
Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 1/Signature 2
Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans/Experiment 2/Signature 1
Exposure to concentrated ambient PM2.5 alters the composition of gut microbiota in a murine model/Experiment 1/Signature 2
Family SES Is Associated with the Gut Microbiome in Infants and Children/Experiment 1
Family SES Is Associated with the Gut Microbiome in Infants and Children/Experiment 1/Signature 1
Family SES Is Associated with the Gut Microbiome in Infants and Children/Experiment 1/Signature 2
Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 1/Signature 2
Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 2/Signature 2
Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 3/Signature 2
Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment/Experiment 4/Signature 2
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 1
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 1/Signature 1
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 1/Signature 2
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 2
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 2/Signature 1
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 2/Signature 2
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 3
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 3/Signature 1
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease/Experiment 3/Signature 2
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease/Experiment 1
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease/Experiment 1/Signature 1
Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease/Experiment 1/Signature 2
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 1
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 1/Signature 1
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 1/Signature 2
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2/Signature 1
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 2/Signature 2
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 3
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 3/Signature 1
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 3/Signature 2
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 4
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 4/Signature 1
Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children/Experiment 4/Signature 2
Fecal microbiome signatures of pancreatic cancer patients/Experiment 3/Signature 2
Fecal microbiome signatures of pancreatic cancer patients/Experiment 4/Signature 1
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 1
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 1/Signature 1
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 1/Signature 2
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2/Signature 1
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 2/Signature 2
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3/Signature 1
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 3/Signature 2
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 4
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 4/Signature 1
Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis/Experiment 4/Signature 2
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 1
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 1/Signature 1
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 1/Signature 2
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 2
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 2/Signature 1
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 2/Signature 2
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 3
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 3/Signature 1
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 4
Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing/Experiment 4/Signature 1
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 1/Signature 1
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 1/Signature 2
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 2/Signature 1
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 3
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients/Experiment 3/Signature 1
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma/Experiment 1/Signature 1
Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota/Experiment 1/Signature 2
Gastro-intestinal and oral microbiome signatures associated with healthy aging
Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1
Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1/Signature 1
Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 1/Signature 2
Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 2
Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 2/Signature 1
Gastro-intestinal and oral microbiome signatures associated with healthy aging/Experiment 2/Signature 2
Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis/Experiment 1/Signature 2
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1/Signature 1
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome/Experiment 1/Signature 2
Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 1/Signature 2
Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment/Experiment 6/Signature 1
Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 3
Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 3/Signature 1
Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico
Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico/Experiment 1
Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico/Experiment 1/Signature 1
Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico/Experiment 1/Signature 2
Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19/Experiment 3/Signature 2
Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease
Gut Microbial Composition and Function Are Altered in Patients with Early Rheumatoid Arthritis/Experiment 1/Signature 2
Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients/Experiment 1/Signature 2
Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China/Experiment 1/Signature 1
Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma/Experiment 1/Signature 2
Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma
Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1
Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1/Signature 1
Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 1/Signature 2
Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2
Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2/Signature 1
Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma/Experiment 2/Signature 2
Gut microbiome and innate immune response patterns in IgE-associated eczema
Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 1
Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 1/Signature 1
Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 2
Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 2/Signature 1
Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3
Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3/Signature 1
Gut microbiome and innate immune response patterns in IgE-associated eczema/Experiment 3/Signature 2
Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention
Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention/Experiment 1
Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention/Experiment 1/Signature 2
Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 1/Signature 1
Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study/Experiment 2/Signature 1
Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 2/Signature 1
Gut microbiome composition is linked to whole grain-induced immunological improvements/Experiment 3/Signature 2
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 1
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 1/Signature 1
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 1/Signature 2
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 2
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 2/Signature 1
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 2/Signature 2
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 3
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 3/Signature 1
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 3/Signature 2
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 4
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia/Experiment 4/Signature 1
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 1
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 1/Signature 2
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 1
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 2/Signature 2
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 3
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors/Experiment 3/Signature 1
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 1
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 1/Signature 1
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 1/Signature 2
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 2
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 2/Signature 1
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 2/Signature 2
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3/Signature 1
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 3/Signature 2
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4/Signature 1
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 4/Signature 2
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5/Signature 1
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 5/Signature 2
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6/Signature 1
Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway/Experiment 6/Signature 2
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients/Experiment 1/Signature 1
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients/Experiment 1/Signature 2
Gut Microbiome of Healthy and Arthritic Dogs/Experiment 1/Signature 2
Gut microbiome of Moroccan colorectal cancer patients/Experiment 1
Gut microbiome of Moroccan colorectal cancer patients/Experiment 1/Signature 1
Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans/Experiment 1/Signature 1
Gut microbiota analysis and its significance in vasovagal syncope in children/Experiment 1/Signature 1
Gut Microbiota and Metabolic Endotoxemia in Young Obese Mexican Subjects/Experiment 1/Signature 2
Gut microbiota and overweight in 3-year old children
Gut microbiota and overweight in 3-year old children/Experiment 1
Gut microbiota and overweight in 3-year old children/Experiment 1/Signature 1
Gut microbiota and overweight in 3-year old children/Experiment 1/Signature 2
Gut microbiota and overweight in 3-year old children/Experiment 2
Gut microbiota and overweight in 3-year old children/Experiment 2/Signature 1
Gut microbiota and overweight in 3-year old children/Experiment 2/Signature 2
Gut microbiota and overweight in 3-year old children/Experiment 3
Gut microbiota and overweight in 3-year old children/Experiment 3/Signature 1
Gut microbiota and overweight in 3-year old children/Experiment 3/Signature 2
Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy/Experiment 3/Signature 1
Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy/Experiment 4/Signature 2
Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 2
Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives
Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives/Experiment 1
Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives/Experiment 1/Signature 1
Gut Microbiota Differences in Children From Distinct Socioeconomic Levels Living in the Same Urban Area in Brazil/Experiment 1/Signature 1
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 1
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 2
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 3
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 4
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 5
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 6
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 7
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 1/Signature 8
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 2
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 3
Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China/Experiment 3/Signature 2
Gut microbiota diversity across ethnicities in the United States
Gut microbiota diversity across ethnicities in the United States/Experiment 1
Gut microbiota diversity across ethnicities in the United States/Experiment 1/Signature 1
Gut microbiota diversity across ethnicities in the United States/Experiment 1/Signature 2
Gut microbiota diversity across ethnicities in the United States/Experiment 2
Gut microbiota diversity across ethnicities in the United States/Experiment 2/Signature 1
Gut microbiota diversity across ethnicities in the United States/Experiment 2/Signature 2
Gut microbiota diversity across ethnicities in the United States/Experiment 3
Gut microbiota diversity across ethnicities in the United States/Experiment 3/Signature 1
Gut microbiota diversity across ethnicities in the United States/Experiment 3/Signature 2
Gut microbiota diversity across ethnicities in the United States/Experiment 4
Gut microbiota diversity across ethnicities in the United States/Experiment 4/Signature 1
Gut microbiota diversity across ethnicities in the United States/Experiment 4/Signature 2
Gut microbiota diversity across ethnicities in the United States/Experiment 5
Gut microbiota diversity across ethnicities in the United States/Experiment 5/Signature 1
Gut microbiota diversity across ethnicities in the United States/Experiment 5/Signature 2
Gut microbiota diversity across ethnicities in the United States/Experiment 6
Gut microbiota diversity across ethnicities in the United States/Experiment 6/Signature 1
Gut microbiota diversity across ethnicities in the United States/Experiment 6/Signature 2
Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis
Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1
Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1/Signature 1
Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis/Experiment 1/Signature 2
Gut microbiota in early pediatric multiple sclerosis: a case-control study
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 1
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 1/Signature 1
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 1/Signature 2
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 2
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 2/Signature 1
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 2/Signature 2
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 3
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 3/Signature 1
Gut microbiota in early pediatric multiple sclerosis: a case-control study/Experiment 3/Signature 2
Gut microbiota is critical for the induction of chemotherapy-induced pain
Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1
Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1/Signature 1
Gut microbiota is critical for the induction of chemotherapy-induced pain/Experiment 1/Signature 2
Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder
Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1
Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1/Signature 1
Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder/Experiment 1/Signature 2
Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT
Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 1
Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 1/Signature 1
Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 2
Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT/Experiment 2/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 1/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 1/Signature 2
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 2
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 2/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 2/Signature 2
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 3
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 3/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 3/Signature 2
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 4
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 4/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 4/Signature 2
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 5
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 5/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 5/Signature 2
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 6
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 7
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 7/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 7/Signature 2
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 8
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 8/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 9
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 9/Signature 1
Gut mucosal microbiome across stages of colorectal carcinogenesis/Experiment 9/Signature 2
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1/Signature 1
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 1/Signature 2
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 2
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 2/Signature 1
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3/Signature 1
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 3/Signature 2
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 4
Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study/Experiment 4/Signature 1
Healthy infants harbor intestinal bacteria that protect against food allergy
Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1
Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1/Signature 1
Healthy infants harbor intestinal bacteria that protect against food allergy/Experiment 1/Signature 2
High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy
High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy/Experiment 1
High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy/Experiment 1/Signature 1
High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy/Experiment 1/Signature 2
High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome
High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1
High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 1/Signature 2
High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 2
High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 2/Signature 1
High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome/Experiment 2/Signature 2
High-Level PM2.5/PM10 Exposure Is Associated With Alterations in the Human Pharyngeal Microbiota Composition/Experiment 1/Signature 2
High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin/Experiment 6/Signature 1
HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota/Experiment 1/Signature 1
HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota/Experiment 1/Signature 2
HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases
HPV infection and bacterial microbiota in breast milk and infant oral mucosa/Experiment 2/Signature 1
HPV infection and bacterial microbiota in breast milk and infant oral mucosa/Experiment 2/Signature 2
Human gut microbiome and risk for colorectal cancer/Experiment 1/Signature 1
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 1
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 1
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 2
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 2
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 1
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 2
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 3
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 1
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 4
Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer/Experiment 4/Signature 1
Human Oral Buccal Microbiomes Are Associated with Farmworker Status and Azinphos-Methyl Agricultural Pesticide Exposure
Human Oral Buccal Microbiomes Are Associated with Farmworker Status and Azinphos-Methyl Agricultural Pesticide Exposure/Experiment 1
Human Oral Buccal Microbiomes Are Associated with Farmworker Status and Azinphos-Methyl Agricultural Pesticide Exposure/Experiment 1/Signature 1
Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study/Experiment 3/Signature 1
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 1
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 1/Signature 1
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 1/Signature 2
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 2
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 2/Signature 1
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 2/Signature 2
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 3
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 3/Signature 1
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 3/Signature 2
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 4
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 4/Signature 1
Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort/Experiment 4/Signature 2
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1/Signature 1
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 1/Signature 2
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 2
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 2/Signature 1
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 2/Signature 2
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 3
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 3/Signature 1
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 3/Signature 2
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 4
IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation/Experiment 4/Signature 1
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 1
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 1/Signature 1
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 1/Signature 2
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2/Signature 1
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 2/Signature 2
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3/Signature 1
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 3/Signature 2
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4/Signature 1
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 4/Signature 2
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5/Signature 1
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 5/Signature 2
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6/Signature 1
Imbalance of Gut Streptococcus, Clostridium, and Akkermansia Determines the Natural Course of Atopic Dermatitis in Infant/Experiment 6/Signature 2
Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa
Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1
Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 1
Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa/Experiment 1/Signature 2
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 1
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 1/Signature 1
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 1/Signature 2
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 2
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 2/Signature 1
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 3
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 3/Signature 1
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 4
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 4/Signature 1
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 4/Signature 2
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 5
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 5/Signature 1
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 6
Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants/Experiment 6/Signature 1
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 1
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 1/Signature 1
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 1/Signature 2
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 2
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 2/Signature 1
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 2/Signature 2
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 3
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 3/Signature 1
Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates/Experiment 3/Signature 2
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1/Signature 1
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 1/Signature 2
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2/Signature 1
Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial/Experiment 2/Signature 2
Implication of the gut microbiome composition of type 2 diabetic patients from northern China
Implication of the gut microbiome composition of type 2 diabetic patients from northern China/Experiment 1
Implication of the gut microbiome composition of type 2 diabetic patients from northern China/Experiment 1/Signature 1
Implication of the gut microbiome composition of type 2 diabetic patients from northern China/Experiment 1/Signature 2
Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk/Experiment 1
Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk/Experiment 1/Signature 1
Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk/Experiment 1/Signature 2
Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome
Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1
Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome/Experiment 1/Signature 1
Infant airway microbiota and topical immune perturbations in the origins of childhood asthma/Experiment 1/Signature 1
Infant gut microbiota and food sensitization: associations in the first year of life
Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 1
Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 1/Signature 1
Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2
Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2/Signature 1
Infant gut microbiota and food sensitization: associations in the first year of life/Experiment 2/Signature 2
Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α and peritoneal fluid flora were associated with infertility in patients with endometriosis/Experiment 1
Influence of cigarette smoking on the human duodenal mucosa-associated microbiota
Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 1
Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 1/Signature 1
Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 2
Influence of cigarette smoking on the human duodenal mucosa-associated microbiota/Experiment 2/Signature 1
Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life
Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life/Experiment 1
Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life/Experiment 1/Signature 1
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 1
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 1/Signature 1
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 1/Signature 2
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 2
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 2/Signature 1
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 2/Signature 2
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 3
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 3/Signature 1
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 3/Signature 2
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 4
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 4/Signature 1
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 4/Signature 2
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 5
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 5/Signature 1
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 5/Signature 2
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 6
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 6/Signature 1
Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome/Experiment 6/Signature 2
Integrated gut virome and bacteriome dynamics in COVID-19 patients
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 1
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 1/Signature 1
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 1/Signature 2
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 2
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 2/Signature 1
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 2/Signature 2
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 3
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 3/Signature 1
Integrated gut virome and bacteriome dynamics in COVID-19 patients/Experiment 3/Signature 2
Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer
Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer/Experiment 1/Signature 1
Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer/Experiment 1/Signature 2
Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer
Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial
Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1
Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 1/Signature 1
Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2
Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial/Experiment 2/Signature 1
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1/Signature 1
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 1/Signature 2
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2/Signature 1
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 2/Signature 2
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3/Signature 1
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 3/Signature 2
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4/Signature 1
Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose/Experiment 4/Signature 2
Intestinal microbiome as a risk factor for urinary tract infections in children
Intestinal microbiome as a risk factor for urinary tract infections in children/Experiment 1
Intestinal microbiome as a risk factor for urinary tract infections in children/Experiment 1/Signature 1
Intestinal microbiome as a risk factor for urinary tract infections in children/Experiment 1/Signature 2
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1/Signature 1
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 1/Signature 2
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 2
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 2/Signature 1
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 3
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 3/Signature 1
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 4
Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients/Experiment 4/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 1/Signature 2
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 2/Signature 2
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 3/Signature 2
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 4/Signature 2
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 5
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 5/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 6
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 6/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 7
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 7/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 8
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 8/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 9/Signature 2
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 10
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 10/Signature 1
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 11
Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics/Experiment 11/Signature 1
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1/Signature 1
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 1/Signature 2
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 2
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 2/Signature 1
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 3
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls/Experiment 3/Signature 1
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 1
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 1/Signature 1
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 2
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 2/Signature 1
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 3
Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study/Experiment 3/Signature 1
Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 1/Signature 2
Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 2/Signature 1
Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3
Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention/Experiment 3/Signature 2
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 1
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 1/Signature 1
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 1/Signature 2
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 2
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 2/Signature 1
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 2/Signature 2
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 3
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 3/Signature 1
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 3/Signature 2
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 4
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 4/Signature 1
Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing/Experiment 4/Signature 2
Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study
Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1
Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1/Signature 1
Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study/Experiment 1/Signature 2
Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity
Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1
Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1/Signature 1
Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 1/Signature 2
Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 2
Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 2/Signature 1
Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity/Experiment 2/Signature 2
Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants
Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 1
Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 1/Signature 1
Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants/Experiment 1/Signature 2
Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis
Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1
Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 1
Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis/Experiment 1/Signature 2
Linking long-term dietary patterns with gut microbial enterotypes
Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1
Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 1
Linking long-term dietary patterns with gut microbial enterotypes/Experiment 1/Signature 2
Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2
Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 1
Linking long-term dietary patterns with gut microbial enterotypes/Experiment 2/Signature 2
Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge
Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1
Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1/Signature 1
Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge/Experiment 1/Signature 2
Low diversity of the gut microbiota in infants with atopic eczema
Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1
Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1/Signature 1
Low diversity of the gut microbiota in infants with atopic eczema/Experiment 1/Signature 2
Lower airway microbiota and mycobiota in children with severe asthma/Experiment 1/Signature 1
Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis
Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 1
Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 1/Signature 1
Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 1/Signature 2
Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 2
Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 2/Signature 1
Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis/Experiment 2/Signature 2
Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults
Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1
Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 1
Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults/Experiment 1/Signature 2
Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study
Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1
Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study/Experiment 1/Signature 1
Maturation of the gut microbiome and risk of asthma in childhood
Maturation of the gut microbiome and risk of asthma in childhood/Experiment 1
Maturation of the gut microbiome and risk of asthma in childhood/Experiment 1/Signature 1
Maturation of the gut microbiome and risk of asthma in childhood/Experiment 1/Signature 2
Maturation of the gut microbiome and risk of asthma in childhood/Experiment 2
Maturation of the gut microbiome and risk of asthma in childhood/Experiment 2/Signature 1
Maturation of the gut microbiome and risk of asthma in childhood/Experiment 2/Signature 2
Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery
Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery/Experiment 1
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 1
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 2
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer/Experiment 1/Signature 3
Metagenome-wide association of gut microbiome features for schizophrenia
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 1
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 1/Signature 2
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2/Signature 1
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2/Signature 2
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 2/Signature 3
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 3
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 3/Signature 1
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 3/Signature 2
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 4
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 4/Signature 1
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 5
Metagenome-wide association of gut microbiome features for schizophrenia/Experiment 5/Signature 1
Metagenomic analyses of the gut microbiota associated with colorectal adenoma
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1/Signature 1
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1/Signature 2
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1/Signature 3
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 1/Signature 4
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2/Signature 1
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2/Signature 2
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2/Signature 3
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 2/Signature 4
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3/Signature 1
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3/Signature 2
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3/Signature 3
Metagenomic analyses of the gut microbiota associated with colorectal adenoma/Experiment 3/Signature 4
Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation/Experiment 1
Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models
Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1
Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1/Signature 1
Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models/Experiment 1/Signature 2
Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota
Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 1
Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 1/Signature 1
Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 2
Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 2/Signature 1
Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 3
Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota/Experiment 3/Signature 1
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 1
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 1/Signature 1
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 1/Signature 2
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 2
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 2/Signature 1
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 3
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 3/Signature 1
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 3/Signature 2
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 4
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 4/Signature 1
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 4/Signature 2
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 5
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 5/Signature 1
Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19/Experiment 5/Signature 2
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 1
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 1/Signature 1
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 1/Signature 2
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 2
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 2/Signature 1
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 2/Signature 2
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 3
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 3/Signature 1
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 3/Signature 2
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 4
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 4/Signature 1
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer/Experiment 4/Signature 2
Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients
Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients/Experiment 1
Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients/Experiment 1/Signature 1
Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients/Experiment 1/Signature 2
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients/Experiment 1
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients/Experiment 1/Signature 1
Metaproteomics characterizes human gut microbiome function in colorectal cancer
Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children
Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1
Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1/Signature 1
Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 1/Signature 2
Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 2
Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 2/Signature 1
Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children/Experiment 2/Signature 2
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1/Signature 1
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 1/Signature 2
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2/Signature 1
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 2/Signature 2
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3/Signature 1
Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease/Experiment 3/Signature 2
Microbe-host interplay in atopic dermatitis and psoriasis
Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1
Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1/Signature 1
Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 1/Signature 2
Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2
Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2/Signature 1
Microbe-host interplay in atopic dermatitis and psoriasis/Experiment 2/Signature 2
Microbial biomarkers of common tongue coatings in patients with gastric cancer
Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 1
Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 1/Signature 1
Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 1/Signature 2
Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 2
Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 2/Signature 1
Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 2/Signature 2
Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 3
Microbial biomarkers of common tongue coatings in patients with gastric cancer/Experiment 3/Signature 1
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 1
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 1/Signature 1
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 1/Signature 2
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 2
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 2/Signature 1
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 2/Signature 2
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 3
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 3/Signature 1
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 3/Signature 2
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 4
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 4/Signature 1
Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients/Experiment 4/Signature 2
Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk
Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk/Experiment 1
Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk/Experiment 1/Signature 1
Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk/Experiment 1/Signature 2
Microbial dysbiosis is associated with human breast cancer
Microbial dysbiosis is associated with human breast cancer/Experiment 1
Microbial dysbiosis is associated with human breast cancer/Experiment 1/Signature 1
Microbial dysbiosis is associated with human breast cancer/Experiment 1/Signature 2
Microbiome and diversity indices during blood stem cells transplantation - new perspectives?
Microbiome and diversity indices during blood stem cells transplantation - new perspectives?/Experiment 1
Microbiome and diversity indices during blood stem cells transplantation - new perspectives?/Experiment 1/Signature 1
Microbiome and diversity indices during blood stem cells transplantation - new perspectives?/Experiment 1/Signature 2
Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase
Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1
Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1/Signature 1
Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 1/Signature 2
Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2
Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 1
Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase/Experiment 2/Signature 2
Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study
Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study/Experiment 1
Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study/Experiment 1/Signature 1
Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study/Experiment 2
Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study/Experiment 2/Signature 1
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 1
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 1/Signature 1
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 1/Signature 2
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 2
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 2/Signature 1
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 2/Signature 2
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 3
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 3/Signature 1
Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion/Experiment 3/Signature 2
Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944)
Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1
Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 1
Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project/Experiment 1/Signature 2
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1/Signature 1
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 1/Signature 2
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2/Signature 1
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 2/Signature 2
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3/Signature 1
Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage/Experiment 3/Signature 2
Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet
Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 1
Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 1/Signature 1
Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 2
Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 2/Signature 1
Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet/Experiment 2/Signature 2
Microbiota changes in a pediatric acute lymphocytic leukemia mouse model
Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 1
Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 1/Signature 1
Microbiota changes in a pediatric acute lymphocytic leukemia mouse model/Experiment 1/Signature 2
Microbiota composition and distribution along the female reproductive tract of women with endometriosis
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 1
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 1/Signature 1
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 2
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 2/Signature 1
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 2/Signature 2
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 3
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 3/Signature 1
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 3/Signature 2
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 4
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 4/Signature 1
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 4/Signature 2
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 5
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 5/Signature 1
Microbiota composition and distribution along the female reproductive tract of women with endometriosis/Experiment 5/Signature 2
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 1
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 1/Signature 1
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 1/Signature 2
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 2
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 2/Signature 1
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 2/Signature 2
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 3
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 3/Signature 1
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 4
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 4/Signature 1
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 5
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 5/Signature 1
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 6
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition/Experiment 6/Signature 1
Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients
Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients/Experiment 1
Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients/Experiment 1/Signature 1
Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients/Experiment 1/Signature 2
Molecular detection of intrauterine microbial colonization in women with endometriosis
Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 1
Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 1/Signature 1
Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 2
Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 2/Signature 1
Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 2/Signature 2
Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 3
Molecular detection of intrauterine microbial colonization in women with endometriosis/Experiment 3/Signature 1
Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis
Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis/Experiment 1
Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis/Experiment 1/Signature 1
Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients
Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1
Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 1
Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients/Experiment 1/Signature 2
Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues
Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1
Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1/Signature 1
Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues/Experiment 1/Signature 2
Mucosal microbiome dysbiosis in gastric carcinogenesis
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 1
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 1/Signature 1
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 1/Signature 2
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 2
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 2/Signature 1
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 2/Signature 2
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 3
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 3/Signature 1
Mucosal microbiome dysbiosis in gastric carcinogenesis/Experiment 3/Signature 2
Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls
Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls/Experiment 1
Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls/Experiment 1/Signature 1
Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls/Experiment 1/Signature 2
Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types
Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types/Experiment 1
Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types/Experiment 1/Signature 1
Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types/Experiment 1/Signature 2
Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?
Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?/Experiment 1
Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?/Experiment 1/Signature 1
Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients
Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients
Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients/Experiment 1
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance
Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1
Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1/Signature 1
Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance/Experiment 1/Signature 2
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1/Signature 1
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 1/Signature 2
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 1
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 2
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 3
Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia/Experiment 2/Signature 4
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 1
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 2
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 3
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 4
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 5
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy/Experiment 1/Signature 6
Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study/Experiment 3/Signature 2
Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study/Experiment 5/Signature 1
Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study/Experiment 5/Signature 2
Oral health and plaque microbial profile in juvenile idiopathic arthritis
Oral health and plaque microbial profile in juvenile idiopathic arthritis/Experiment 1
Oral health and plaque microbial profile in juvenile idiopathic arthritis/Experiment 1/Signature 1
Oral health and plaque microbial profile in juvenile idiopathic arthritis/Experiment 1/Signature 2
Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2
Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 1
Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients/Experiment 2/Signature 2
Oral microbiome and history of smoking and colorectal cancer
Oral microbiome and history of smoking and colorectal cancer/Experiment 1
Oral microbiome and history of smoking and colorectal cancer/Experiment 2
Oral microbiome and history of smoking and colorectal cancer/Experiment 2/Signature 1
Oral microbiome and history of smoking and colorectal cancer/Experiment 3
Oral microbiome and history of smoking and colorectal cancer/Experiment 3/Signature 1
Oral microbiome and history of smoking and colorectal cancer/Experiment 4
Oral microbiome and history of smoking and colorectal cancer/Experiment 4/Signature 1
Oral microbiome and history of smoking and colorectal cancer/Experiment 4/Signature 2
Oral microbiome and obesity in a large study of low-income and African-American populations
Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1
Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 1/Signature 1
Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2
Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 1
Oral microbiome and obesity in a large study of low-income and African-American populations/Experiment 2/Signature 2
Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy
Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 1
Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 1/Signature 1
Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 2
Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 2/Signature 1
Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 3
Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy/Experiment 3/Signature 1
Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma
Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1
Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1/Signature 1
Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 1/Signature 2
Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2
Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2/Signature 1
Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma/Experiment 2/Signature 2
Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China
Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1
Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1/Signature 1
Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 1/Signature 2
Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2
Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2/Signature 1
Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China/Experiment 2/Signature 2
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1/Signature 1
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 1/Signature 2
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2/Signature 1
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 2/Signature 2
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3/Signature 1
Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging/Experiment 3/Signature 2
Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children
Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1
Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 1
Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children/Experiment 1/Signature 2
Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis
Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1
Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1/Signature 1
Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis/Experiment 1/Signature 2
Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis
Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 1
Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 1/Signature 1
Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis/Experiment 1/Signature 2
Oral status in patients with early rheumatoid arthritis: a prospective, case-control study
Oral status in patients with early rheumatoid arthritis: a prospective, case-control study/Experiment 1/Signature 2
Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota
Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1
Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 1
Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota/Experiment 1/Signature 2
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1/Signature 1
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 1/Signature 2
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 2
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 2/Signature 1
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 2/Signature 2
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 3
Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions/Experiment 3/Signature 1
Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls
Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls/Experiment 1
Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls/Experiment 1/Signature 1
Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls/Experiment 1/Signature 2
Penile Anaerobic Dysbiosis as a Risk Factor for HIV Infection/Experiment 1/Signature 2
Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis
Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1
Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1/Signature 1
Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis/Experiment 1/Signature 2
Perturbations of the Gut Microbiome and Metabolome in Children with Calcium Oxalate Kidney Stone Disease
Phenylketonuric diet negatively impacts on butyrate production
Phenylketonuric diet negatively impacts on butyrate production/Experiment 1
Phenylketonuric diet negatively impacts on butyrate production/Experiment 1/Signature 1
Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana
Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1
Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 1
Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana/Experiment 1/Signature 2
Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder
Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1
Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 1
Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder
Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder/Experiment 1
Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 1
Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder/Experiment 1/Signature 2
Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)
Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 1
Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 1/Signature 1
Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 1/Signature 2
Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 2
Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 2/Signature 1
Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome)/Experiment 2/Signature 2
Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study
Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 1
Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 1/Signature 1
Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 1/Signature 2
Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 2
Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 2/Signature 1
Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study/Experiment 2/Signature 2
Potential of fecal microbiota for early-stage detection of colorectal cancer
Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 1
Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 1/Signature 1
Potential of fecal microbiota for early-stage detection of colorectal cancer/Experiment 1/Signature 3
Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity
Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1
Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 1
Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 1/Signature 2
Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2
Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 1
Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity/Experiment 2/Signature 2
Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort
Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1
Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 1/Signature 1
Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2
Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort/Experiment 2/Signature 1
Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 1
Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 1/Signature 1
Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 2
Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study/Experiment 2/Signature 1
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 1
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 1
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 1/Signature 2
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 2
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 2/Signature 1
Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome/Experiment 2/Signature 2
Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units
Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1
Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 1
Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 1/Signature 2
Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2
Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 1
Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units/Experiment 2/Signature 2
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 1
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection/Experiment 1/Signature 2
Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure
Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1
Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 1
Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure/Experiment 1/Signature 2
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 1
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 1
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 1/Signature 2
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 2
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 1
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 2/Signature 2
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 3
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 1
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 3/Signature 2
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 4
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 4/Signature 1
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 4/Signature 2
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 5
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 5/Signature 1
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 5/Signature 3
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 6
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 6/Signature 1
Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer/Experiment 6/Signature 2
Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage
Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1
Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 1
Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage/Experiment 1/Signature 2
Protection of the Human Gut Microbiome From Antibiotics
Protection of the Human Gut Microbiome From Antibiotics/Experiment 1
Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 1
Protection of the Human Gut Microbiome From Antibiotics/Experiment 1/Signature 2
Protection of the Human Gut Microbiome From Antibiotics/Experiment 2
Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 1
Protection of the Human Gut Microbiome From Antibiotics/Experiment 2/Signature 2
Protection of the Human Gut Microbiome From Antibiotics/Experiment 3
Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 1
Protection of the Human Gut Microbiome From Antibiotics/Experiment 3/Signature 2
Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls
Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1
Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 1
Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls/Experiment 1/Signature 2
Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children
Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1
Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children/Experiment 1/Signature 1
Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1
Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 1
Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry/Experiment 1/Signature 2
Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer
Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis
Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1
Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 1
Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 1/Signature 2
Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2
Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis/Experiment 2/Signature 1
Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria
Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1
Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1/Signature 1
Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 1/Signature 2
Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 2
Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria/Experiment 2/Signature 1
Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART
Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1
Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1/Signature 1
Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 1/Signature 2
Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 2
Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART/Experiment 2/Signature 1
Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation
Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1
Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 1
Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation/Experiment 1/Signature 2
Reduced microbiome alpha diversity in young patients with ADHD
Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1
Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 1
Reduced microbiome alpha diversity in young patients with ADHD/Experiment 1/Signature 2
Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis/Experiment 1/Signature 1
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 1
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 1/Signature 1
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 1/Signature 2
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 2
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 2/Signature 1
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 2/Signature 2
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 3
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 3/Signature 1
Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study/Experiment 3/Signature 2
Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study
Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1
Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 1
Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study/Experiment 1/Signature 2
Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota
Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1
Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1/Signature 1
Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 1/Signature 2
Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2
Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2/Signature 1
Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota/Experiment 2/Signature 2
Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 1
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 1/Signature 2
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 1
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 2/Signature 2
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 1
Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study/Experiment 3/Signature 2
Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients
Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 1
Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 1/Signature 1
Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 1/Signature 2
Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 2
Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 2/Signature 1
Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients/Experiment 2/Signature 2
Salivary microbiota and inflammation-related proteins in patients with psoriasis
Salivary microbiota and inflammation-related proteins in patients with psoriasis
Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study
Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 1
Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 1/Signature 1
Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 1/Signature 2
Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 2
Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 2/Signature 1
Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study/Experiment 2/Signature 2
SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition
SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition/Experiment 1
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 1
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 1/Signature 1
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 1/Signature 2
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 2
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 2/Signature 1
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome/Experiment 2/Signature 2
Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis
Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1
Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1/Signature 5
Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis/Experiment 1/Signature 8
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 1
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 1/Signature 1
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 1/Signature 2
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 2
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 2/Signature 1
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 3
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 3/Signature 1
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 3/Signature 2
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 4
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 4/Signature 1
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 5
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 5/Signature 1
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 5/Signature 2
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 6
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 6/Signature 1
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 6/Signature 2
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 7
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 7/Signature 1
Sex-specific effects of PM2.5 maternal exposure on offspring's serum lipoproteins and gut microbiota/Experiment 7/Signature 2
Sex-specific impact of asthma during pregnancy on infant gut microbiota
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1/Signature 1
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 1/Signature 2
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2/Signature 1
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 2/Signature 2
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 3
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 3/Signature 1
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 4
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 4/Signature 1
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5/Signature 1
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 5/Signature 2
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 6
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 6/Signature 1
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 7
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 7/Signature 1
Sex-specific impact of asthma during pregnancy on infant gut microbiota/Experiment 7/Signature 2
Shift in skin microbiota of Western European women across aging
Shift in skin microbiota of Western European women across aging/Experiment 1
Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 1
Shift in skin microbiota of Western European women across aging/Experiment 1/Signature 2
Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma
Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 1
Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 1/Signature 1
Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 1/Signature 2
Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 2
Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma/Experiment 2/Signature 1
Shifts in the Fecal Microbiota Associated with Adenomatous Polyps
Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1
Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 1
Shifts in the Fecal Microbiota Associated with Adenomatous Polyps/Experiment 1/Signature 2
Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial
Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1
Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 1
Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial/Experiment 1/Signature 2
Short-term effect of antibiotics on human gut microbiota
Short-term effect of antibiotics on human gut microbiota/Experiment 1
Short-term effect of antibiotics on human gut microbiota/Experiment 1/Signature 1
Short-term effect of antibiotics on human gut microbiota/Experiment 1/Signature 2
Short-term effect of antibiotics on human gut microbiota/Experiment 2
Short-term effect of antibiotics on human gut microbiota/Experiment 2/Signature 1
Short-term effect of antibiotics on human gut microbiota/Experiment 2/Signature 2
Short-term effect of antibiotics on human gut microbiota/Experiment 3
Short-term effect of antibiotics on human gut microbiota/Experiment 3/Signature 1
Short-term effect of antibiotics on human gut microbiota/Experiment 3/Signature 2
Short-term effect of antibiotics on human gut microbiota/Experiment 4
Short-term effect of antibiotics on human gut microbiota/Experiment 4/Signature 1
Short-term effect of antibiotics on human gut microbiota/Experiment 4/Signature 2
Short-term effect of antibiotics on human gut microbiota/Experiment 5
Short-term effect of antibiotics on human gut microbiota/Experiment 5/Signature 1
Short-term effect of antibiotics on human gut microbiota/Experiment 5/Signature 2
Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood
Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1
Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 1
Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood/Experiment 1/Signature 2
Signatures of COVID-19 severity and immune response in the respiratory tract microbiome
Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model
Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1
Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1/Signature 1
Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model/Experiment 1/Signature 2
Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients
Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1
Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 1
Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 1/Signature 2
Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2
Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients/Experiment 2/Signature 1
Six-month follow-up of gut microbiota richness in patients with COVID-19
Six-month follow-up of gut microbiota richness in patients with COVID-19/Experiment 1
Six-month follow-up of gut microbiota richness in patients with COVID-19/Experiment 2
Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year
Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year/Experiment 1
Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year/Experiment 1/Signature 1
Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study
Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1
Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 1
Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study/Experiment 1/Signature 2
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 1
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 1/Signature 1
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 1/Signature 2
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 2
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 2/Signature 1
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 2/Signature 2
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 3
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 3/Signature 1
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4/Signature 1
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 4/Signature 2
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 5
Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study/Experiment 5/Signature 1
Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults
Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults/Experiment 1
Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults/Experiment 1/Signature 1
Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults/Experiment 1/Signature 2
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 1
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 1/Signature 1
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 1/Signature 2
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 2
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 2/Signature 1
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 2/Signature 2
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 3
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 3/Signature 1
Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study/Experiment 3/Signature 2
Study 449
Study 449/Experiment 1
Study 449/Experiment 1/Signature 1
Study 449/Experiment 1/Signature 2
Study 501
Study 501/Experiment 1
Study 501/Experiment 1/Signature 1
Study 513
Study 513/Experiment 1
Study 513/Experiment 1/Signature 1
Study 513/Experiment 2
Study 513/Experiment 2/Signature 1
Study 562/Experiment 1/Signature 3
Study 562/Experiment 4/Signature 2
Study 562/Experiment 5/Signature 1
Study 562/Experiment 5/Signature 2
Study 562/Experiment 7/Signature 1
Study 562/Experiment 8/Signature 1
Study 562/Experiment 8/Signature 2
Study 668
Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children
Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1
Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 1
Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 1/Signature 2
Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 2
Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 2/Signature 1
Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children/Experiment 2/Signature 2
Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients
Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1
Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 1/Signature 1
Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2
Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 1
Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients/Experiment 2/Signature 2
Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis
Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis/Experiment 1
Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis/Experiment 1/Signature 1
Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis/Experiment 1/Signature 2
Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study
Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study/Experiment 1
Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study/Experiment 1/Signature 1
Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study/Experiment 1/Signature 2
Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health
Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 1
Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 1/Signature 1
Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health/Experiment 1/Signature 2
Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3
Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 1
Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 3/Signature 2
Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4
Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 1
Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis/Experiment 4/Signature 2
Suppression of the gut microbiome ameliorates age-related arterial dysfunction and oxidative stress in mice
Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development
Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development/Experiment 1
Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development/Experiment 1/Signature 1
Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults
Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 1
Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 2
Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 3
Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 4
Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 5
Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 6
Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults/Experiment 7
Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy
Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1
Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 1
Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 2
Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 3
Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy/Experiment 1/Signature 4
The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes
The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1
The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1/Signature 1
The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes/Experiment 1/Signature 2
The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients
The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients/Experiment 1
The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients/Experiment 1/Signature 1
The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients/Experiment 1/Signature 2
The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing
The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing/Experiment 1
The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing/Experiment 1/Signature 1
The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood
The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood/Experiment 1
The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood/Experiment 1/Signature 1
The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood/Experiment 1/Signature 2
The Association Between Smoking and Gut Microbiome in Bangladesh
The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1
The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1/Signature 1
The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1/Signature 2
The Association Between Smoking and Gut Microbiome in Bangladesh/Experiment 1/Signature 3
The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence
The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence/Experiment 1
The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence/Experiment 1/Signature 1
The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence/Experiment 1/Signature 2
The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia
The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia/Experiment 1
The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia/Experiment 1/Signature 1
The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia/Experiment 1/Signature 2
The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients
The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1
The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1/Signature 1
The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients/Experiment 1/Signature 2
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 1
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 1/Signature 2
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 1
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 2/Signature 2
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 1
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 3/Signature 2
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 1
The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis/Experiment 4/Signature 2
The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial
The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 3/Signature 1
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients/Experiment 3/Signature 2
The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ
The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ/Experiment 1
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC/Experiment 1/Signature 1
The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health
The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health/Experiment 1
The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health/Experiment 1/Signature 1
The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health/Experiment 1/Signature 2
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 1
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 1/Signature 1
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 2
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 2/Signature 1
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 2/Signature 2
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 3
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 3/Signature 1
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 4
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 4/Signature 1
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 5
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 5/Signature 1
The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls/Experiment 5/Signature 2
The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics
The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1
The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1/Signature 1
The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics/Experiment 1/Signature 2
The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study
The gut microbiome composition associates with bipolar disorder and illness severity
The gut microbiome composition associates with bipolar disorder and illness severity/Experiment 1
The gut microbiome composition associates with bipolar disorder and illness severity/Experiment 1/Signature 1
The gut microbiome of Mexican children affected by obesity
The gut microbiome of Mexican children affected by obesity
The gut microbiome of Mexican children affected by obesity/Experiment 1
The gut microbiome of Mexican children affected by obesity/Experiment 1
The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 1
The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 1
The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 2
The gut microbiome of Mexican children affected by obesity/Experiment 1/Signature 2
The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1
The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1/Signature 1
The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients/Experiment 1/Signature 2
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 1
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 1/Signature 1
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 1/Signature 2
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 2
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 2/Signature 1
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3/Signature 1
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 3/Signature 2
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 4
The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness/Experiment 4/Signature 1
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 1
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 1/Signature 1
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 1/Signature 2
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 2
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 2/Signature 1
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 2/Signature 2
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 3
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 3/Signature 1
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 3/Signature 2
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 4
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 4/Signature 1
The gut microbiota of Colombians differs from that of Americans, Europeans and Asians/Experiment 4/Signature 2
The human gut microbiome as a screening tool for colorectal cancer
The human gut microbiome as a screening tool for colorectal cancer/Experiment 1
The human gut microbiome as a screening tool for colorectal cancer/Experiment 1/Signature 1
The human gut microbiome as a screening tool for colorectal cancer/Experiment 1/Signature 2
The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients
The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects
The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 1
The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 2
The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects/Experiment 3
The impact of postnatal antibiotics on the preterm intestinal microbiome
The impact of postnatal antibiotics on the preterm intestinal microbiome/Experiment 1
The impact of postnatal antibiotics on the preterm intestinal microbiome/Experiment 1/Signature 1
The influence of in vitro pectin fermentation on the human fecal microbiome
The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1
The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1/Signature 1
The influence of in vitro pectin fermentation on the human fecal microbiome/Experiment 1/Signature 2
The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology
The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1
The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1/Signature 1
The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 1/Signature 2
The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 2
The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology/Experiment 2/Signature 1
The intestinal microflora in allergic Estonian and Swedish 2-year-old children
The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1
The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1/Signature 1
The intestinal microflora in allergic Estonian and Swedish 2-year-old children/Experiment 1/Signature 2
The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy
The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1
The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 1
The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 2
The lower respiratory tract microbiome of critically ill patients with COVID-19
The lower respiratory tract microbiome of critically ill patients with COVID-19/Experiment 1
The lower respiratory tract microbiome of critically ill patients with COVID-19/Experiment 1/Signature 1
The lower respiratory tract microbiome of critically ill patients with COVID-19/Experiment 1/Signature 2
The Microbiome of Prostate Fluid Is Associated With Prostate Cancer
The Microbiome of Prostate Fluid Is Associated With Prostate Cancer
The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1
The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1
The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 1
The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 1
The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 2
The Microbiome of Prostate Fluid Is Associated With Prostate Cancer/Experiment 1/Signature 2
The microbiota of the gut in preschool children with normal and excessive body weight
The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1
The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 1
The microbiota of the gut in preschool children with normal and excessive body weight/Experiment 1/Signature 2
The nasal microbiome in asthma/Experiment 1
The nasal microbiome in asthma/Experiment 1/Signature 1
The nasal microbiome in asthma/Experiment 2
The nasal microbiome in asthma/Experiment 2/Signature 1
The nasal microbiome in asthma/Experiment 4
The nasal microbiome in asthma/Experiment 4/Signature 1
The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function/Experiment 1/Signature 1
The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function/Experiment 1/Signature 2
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 1/Signature 1
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 2/Signature 1
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 3/Signature 1
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4
The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study/Experiment 4/Signature 1
The oral microbiota in colorectal cancer is distinctive and predictive
The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1
The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1/Signature 1
The oral microbiota in colorectal cancer is distinctive and predictive/Experiment 1/Signature 2
The oropharyngeal microbiome is altered in individuals with schizophrenia and mania
The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 1
The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 1/Signature 1
The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 1/Signature 2
The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 2
The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 2/Signature 1
The oropharyngeal microbiome is altered in individuals with schizophrenia and mania/Experiment 2/Signature 2
The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers
The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 1
The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 1/Signature 1
The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 2
The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 2/Signature 1
The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers/Experiment 2/Signature 2
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 1
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 1/Signature 1
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 1/Signature 2
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 2
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 3
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 3/Signature 1
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 3/Signature 2
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 4
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 4/Signature 1
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 4/Signature 2
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 5
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 5/Signature 1
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 5/Signature 2
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma/Experiment 5/Signature 3
The relationship between cigarette smoking and the tongue microbiome in an East Asian population
The relationship between cigarette smoking and the tongue microbiome in an East Asian population/Experiment 1
The relationship between cigarette smoking and the tongue microbiome in an East Asian population/Experiment 1/Signature 1
The relationship between cigarette smoking and the tongue microbiome in an East Asian population/Experiment 1/Signature 2
The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer/Experiment 1/Signature 1
The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer/Experiment 1/Signature 2
The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis
The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 1
The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 1/Signature 1
The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 1/Signature 2
The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 2
The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 2/Signature 1
The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis/Experiment 2/Signature 2
The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study
The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1
The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1/Signature 1
The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 1/Signature 2
The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2
The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2/Signature 1
The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study/Experiment 2/Signature 2
The semen microbiome and its relationship with local immunology and viral load in HIV infection/Experiment 1/Signature 1
The skin microbiome is different in pediatric versus adult atopic dermatitis
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1/Signature 1
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1/Signature 2
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1/Signature 3
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 1/Signature 4
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 2
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 2/Signature 1
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 2/Signature 2
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3/Signature 1
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3/Signature 2
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3/Signature 3
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 3/Signature 4
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 4
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 4/Signature 1
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 5
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 5/Signature 1
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 6
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 6/Signature 1
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7/Signature 1
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7/Signature 2
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7/Signature 3
The skin microbiome is different in pediatric versus adult atopic dermatitis/Experiment 7/Signature 4
The subgingival microbiome in patients with established rheumatoid arthritis
The subgingival microbiome in patients with established rheumatoid arthritis/Experiment 1
The subgingival microbiome in patients with established rheumatoid arthritis/Experiment 1/Signature 1
The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study
The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study/Experiment 1
The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study/Experiment 1/Signature 1
Tongue microbiome of smokeless tobacco users
Tongue microbiome of smokeless tobacco users/Experiment 1
Tongue microbiome of smokeless tobacco users/Experiment 1/Signature 1
Tongue microbiome of smokeless tobacco users/Experiment 1/Signature 2
Tumour-associated and non-tumour-associated microbiota in colorectal cancer
Tumour-associated and non-tumour-associated microbiota in colorectal cancer/Experiment 1
Twice-daily application of HIV microbicides alter the vaginal microbiota
Twice-daily application of HIV microbicides alter the vaginal microbiota/Experiment 1
Twice-daily application of HIV microbicides alter the vaginal microbiota/Experiment 1/Signature 1
Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation/Experiment 1/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 1/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 1/Signature 2
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 2
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 2/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 2/Signature 2
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 3
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 3/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 3/Signature 2
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 4
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 4/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 4/Signature 2
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 5
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 5/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 6
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 6/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 6/Signature 2
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 7
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 7/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 7/Signature 2
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 8
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 8/Signature 1
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism/Experiment 8/Signature 2
Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study
Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study/Experiment 1
Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study/Experiment 1/Signature 1
Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease
Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease/Experiment 1
Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease/Experiment 1/Signature 1
Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease/Experiment 1/Signature 2
Variations of Tongue Coating Microbiota in Patients with Gastric Cancer
Variations of Tongue Coating Microbiota in Patients with Gastric Cancer/Experiment 1
Variations of Tongue Coating Microbiota in Patients with Gastric Cancer/Experiment 1/Signature 1
Variations of Tongue Coating Microbiota in Patients with Gastric Cancer/Experiment 1/Signature 2